| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424175100 | Binds hapten, hapten-carrier complex, or specifically-identified chemical structure (e.g., drug, etc.) | 49 |
| 20080317764 | ANTIBODIES AGAINST 25-HYDROXYVITAMIN D - The present invention concerns processes for producing antibodies against 25-hydroxyvitamin D, the antibodies produced according to the invention as well as methods for the detection of 25-hydroxyvitamin D using these antibodies. | 12-25-2008 |
| 20090175885 | METHOD OF CONTROLLING INSECT PESTS IN COTTON - An assay system is provided in which gossypol is used as a biological marker to detect evolved resistance of insects to Bt cotton. Detection of gossypol using a monoclonal antibody ELISA-based protocol enables at risk populations of insects to be evaluated for evolved resistance to Bt present in a genetically modified cotton. | 07-09-2009 |
| 20090214575 | Annexin II and uses thereof - The present invention relates to the field of diagnosis and treatment of neurodegenerative diseases, ischemic events, and central nervous system injury, and provides compositions and methods for alleviation or reduction of the symptoms and signs associated with damaged neuronal tissues whether resulting from tissue trauma, or from chronic or acute degenerative changes. | 08-27-2009 |
| 20090258028 | Methods Of Forming Coatings For Implantable Medical Devices For Controlled Release Of A Peptide And A Hydrophobic Drug - This invention is generally related to methods of forming coatings for implantable medical devices, such as drug delivery vascular stents. The methods are for forming coatings to control the release of a peptide such as RGD, and a hydrophobic drug. Both single layer and multiple layer coating constructs are encompassed in the various embodiments of the present invention. | 10-15-2009 |
| 20090311273 | TREATMENT OF MULTIPLE SCLEROSIS AND/OR RHEUMATOID ARTHRITIS - The invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament utilized for the treatment of multiple sclerosis and/or rheumatoid arthritis in a subject that is preferably a primate or a human. In another embodiment, the invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament that is utilized for depleting monocytes in subjects suffering from multiple sclerosis and/or rheumatoid arthritis. The invention further relates to corresponding in vitro methods and therapeutic methods. And antibody which binds to CD 14, for example, can be used in addition to the antibody that can bind to CCR2. | 12-17-2009 |
| 20100034835 | USE OF INHIBITORS OF LEUKOTRIENE B4 RECEPTOR BLT2 FOR TREATING ASTHMA - The present invention relates to a new use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma. More particularly, the present invention relates to a pharmaceutical composition for treating asthma comprising BLT2 inhibitors and a method for treating asthma using BLT2 inhibitors. | 02-11-2010 |
| 20100055114 | USE OF INTEGRIN ALPHA 10 BINDING ANTIBODY TO MODULATE EXTRACELLULAR MATRIX (CARTILAGE) TURNOVER - The present invention relates to a novel use of alpha10, or a heterodimer thereof, for affecting cartilage extracellular matrix (ECM) turnover. Further, it relates to the use of a binding entity binding specifically to alpha10, or a heterodimer thereof, in the preparation of a medicament for treating a condition affecting ECM, such as rheumatoid arthritis and osteoarthritis. In particular, the invention relates to a method of treating an individual with a condition affecting ECM turnover, comprising administering to the individual an effective amount of a binding agent entity binding specifically to alpha10, or a heterodimer thereof. | 03-04-2010 |
| 20100062003 | THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BASED ON THE ROLE OF THE CXCR-4 GENE IN TUMORIGENESIS - The present invention relates to the identification of a novel role of CXCR-4 in cell transformation and aberrant cellular proliferation. In particular, the present invention relates to the altered gene expression of CXCR-4 in a number of primary tumors and cell lines derived from tumors, in addition to, the altered gene expression of ligands for CXCR-4. Further, the present invention relates, in part, to the Applicant's surprising discovery that the inhibition of CXCR-4 gene expression or the inhibition of CXCR-4 activity in transformed cells reverses the transformed phenotype. | 03-11-2010 |
| 20100062004 | AMINO ACID SEQUENCES DIRECTED AGAINST GPCRS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF GPCR-RELATED DISEASES AND DISORDERS - The present invention relates to amino acid sequences that are directed G-protein coupled receptors (GPCRs), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes mentioned herein. | 03-11-2010 |
| 20100062005 | Methods and Compounds for Lymphoma Cell Detection and Isolation - Compositions comprising a purified and/or isolated antibody, humanized antibodies, precipitates and anti-sera that specifically bind to or are otherwise directed against ROR1 protein. The compositions may be used for detecting ROR1 in a sample from a subject that is suspected or known to contain cancer cells. The ROR1 antibodies are especially useful in identifying and treating lymphomas and ademocarcinomas. Vaccines and related methods for protecting a subject against diseases that involve expression of ROR1 are also provided, as are human anti-sera effective in abrogating interactions between Wnt5a protein and ROR1 that contribute to the survival of certain cancer cells, such as CLL cells. | 03-11-2010 |
| 20100092493 | Modulation of Complement System Activation for Treatment of Bleeding-Related Inflammation - This invention provides, inter alia, methods and compositions for treating, reducing the incidence of, reducing the severity of, or delaying onset or advancement, of synovitis and/or bleeding-associated inflammation in a subject in need thereof. The compositions comprise, and methods make use of, an effective amount of an agent, which abrogates or diminishes activation of the C5aR complement pathway in said subject, and optionally other therapeutic agents including a coagulation factor, other hemostatic factor, and/or second anti-inflammatory agent. | 04-15-2010 |
| 20100119527 | N-CADHERIN: TARGET FOR CANCER DIAGNOSIS AND THERAPY - The present invention provides methods of diagnosis, providing a prognosis and a therapeutic target for the treatment of cancers that express N-cadherin, including prostrate and bladder cancers. | 05-13-2010 |
| 20100143385 | METHODS FOR REDUCING PHOSPHATE ABSORPTION - It is disclosed here a method for reducing phosphate absorption in a human or non-human animal subject wherein the subject consumes a diet containing phytic acid or phytate and either has or is at risk of developing hyperphosphatemia. The method includes the step of administering orally to the subject an anti-phytic acid (C | 06-10-2010 |
| 20100143386 | FGFR4 Promotes Cancer Cell Resistance in Response to Chemotherapeutic Drugs - The present invention relates to Fibroblast-Growth Factor Receptor 4 (FGRF4) inhibitors for co-administration with a therapeutic procedure or/and agent for the prevention, alleviation or/and treatment of a hyperproliferative disorder, e.g. cancer, such as chemotherapy resistant cancer. Further, the present invention relates to a diagnostic procedure wherein expression status and/or polymorphisms of the FGFR | 06-10-2010 |
| 20100183632 | Antibody Therapy For Modulating Function Of Intestinal Receptors - The present invention provides pharmaceutical compositions formulated for direct delivery to the GI tract of a patient comprising an antibody specific for a target apical intestinal receptor. The present invention further provides methods of treating diseases and conditions in a patient comprising administering directly to the GI tract of the patient, compositions of the present invention wherein modulation of the target apical intestinal receptor by the antibody treats the condition. | 07-22-2010 |
| 20100233188 | ANTIBODIES AND PHARAMCETICAL COMPOSITIONS CONTAINING SAME USEFUL FOR INHIBITING ACTIVITY OF METALLOPROTEINS - The present invention relates to a compound having the general Formula (I): | 09-16-2010 |
| 20100260784 | PAI-1 BINDING MODULATORS FOR THE TREATMENT OF OCULAR DISORDERS - The invention concerns in one embodiment a method for treating glaucoma or elevated IOP in a patient comprising administering to the patient an effective amount of a composition comprising an agent that modulates PAI-1 binding to vitronectin. In another embodiment, the invention concerns a method of manufacturing a compound to be used as a treatment for glaucoma or elevated IOP comprising providing a candidate substance suspected of modulating PAI-1 binding, selecting the compound by assessing the ability of the candidate substance to decrease the amount of active PAI-1 in the trabecular meshwork of a subject suffering from glaucoma or elevated PAI-1, and manufacturing the selected compound. | 10-14-2010 |
| 20100266619 | Neutralizing Antibodies and Methods of Use Thereof - This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies. | 10-21-2010 |
| 20110052608 | NOVEL ANTIBODIES AGAINST PRION PROTEIN AND USES THEREOF - The present invention relates to a novel antibody which selectively binds to the disease associated form of prion protein (PrP | 03-03-2011 |
| 20110070247 | PROTEIN MODULATORS - The present invention relates to modulators of the Neuregulin (NRG) family, particularly NRG1 and more particularly NRG1β, and most particularly NRG1β1. The present invention also relates to the use of such modulators to inhibit goblet cell hyperplasia and therefore also relates to the use of such modulators in the treatment or prevention of human diseases and disorders featuring pathological mucus production such as COPD, CF, chronic bronchitis and asthma. | 03-24-2011 |
| 20110142858 | Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation - Unglycosylated anti-amyloid antibodies maintained all the antigen recognition functions of the native glycosylated anti-amyloid antibodies but without, or with a much reduced, property of triggering Fc receptor-mediated inflammation response in the brain. Such unglycosylated antibodies can be used in a method for preventing, inhibiting, or treating a disease or disorder characterized by amyloid aggregation with a diminished risk of triggering or exacerbating neuroinflammation. | 06-16-2011 |
| 20110182918 | Personalized drug treatment and smoking cessation kit and method - Described are smoking cessation devices and kits for determining an advantageous time for a subject to quit smoking, and/or for extending the duration of smoking abstinence, based on serum levels of anti-nicotine antibodies, and personalized drug treatment methods, including methods and kits for the treatment and prevention of drug addiction, drug use and drug abuse, which include determining the subject's pre-vaccine levels of antibodies specific for the drug hapten at issue. Related methods are also described. | 07-28-2011 |
| 20110217320 | HAPTEN-CARRIER CONJUGATES FOR TREATING AND PREVENTING NICOTINE ADDICTION - Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction. | 09-08-2011 |
| 20110268750 | CHIMERIC POLYNUCLEOTIDES AND POLYPEPTIDES ENABLING SECRETION OF A POLYPEPTIDE OF INTEREST IN ASSOCIATION WITH EXOSOMES AND USE THEREOF FOR THE PRODUCTION OF IMMUNOGENIC COMPOSITIONS - The present invention concerns a chimeric polypeptide comprising several polypeptide domains, which is capable of being secreted in association with membrane vesicles and in particular exosomes. | 11-03-2011 |
| 20110287031 | Covalently reactive transition state analogs and methods of use thereof - Improved methods for the production, selection and inhibition of catalytic antibodies are disclosed. | 11-24-2011 |
| 20110305715 | ANTIBODIES TO 3-HYDROXYCOTININE AND METHODS OF USE THEREOF - The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to 3-hydroxycotinine (3HC). The invention also provides compositions containing these antibodies and fragments thereof, and to their use in diagnostic and therapeutic applications for diseases involving nicotine activity (e.g., smoking and/or smokeless tobacco use). | 12-15-2011 |
| 20120027780 | ANTICOAGULANT ANTIDOTES - The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants. | 02-02-2012 |
| 20120082684 | DIAGNOSIS AND TREATMENT OF CELL PROLIFERATION AND DIFFERENTIATION DISORDERS BASED ON THE FMN2 GENE - The present invention provides methods for diagnosing cell proliferation and/or differentiation disorders, compounds and methods for treating the same and methods for identifying agents potentially useful in the treatment of cell proliferation and/or differentiation disorders. | 04-05-2012 |
| 20120225087 | NICOTINE HAPTENS, IMMUNOCONJUGATES AND THEIR USES - The present invention provides novel nicotine hapten compounds and nicotine immunoconjugates which can be used for in vivo production of antibodies that specifically bind to nicotine. The invention also provides methods of using vaccines comprising the nicotine immunoconjugates in active or passive immunization protocols. The compositions and methods of the invention are useful for prevention and treatment of nicotine addiction. | 09-06-2012 |
| 20120258123 | BIOMARKERS FOR SENSITIVE DETECTION OF STATIN-INDUCED MUSCLE TOXICITY - The present invention inter alia provides a method, and uses thereof, of predicting statin-induced muscle toxicity or its complications, such as myalgia, myopathy and rhabdomyolysis, by detecting the lipid concentrations or lipid-lipid concentration ratios of a biological sample and comparing them to a control. This method has identified lipid markers that are more specific and sensitive in detecting these statin-induced muscle toxicity than the currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, statin-induced muscle toxicity. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of statin-induced muscle toxicity. | 10-11-2012 |
| 20120276123 | ANTICOAGULANT ANTIDOTES - The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants. | 11-01-2012 |
| 20130142813 | ANTIBODY BINDING TO LYSOPHOSPHATIDYLGLUCOSIDE, AND COMPOSITION COMPRISING THE SAME - In order to identify a factor demonstrating a repellent effect on axon extension of a neuron, lysophosphatidylglucoside (LPG) has been found to have an activity as a chemorepellent effect on axon guidance of a DRG sensory neuron specific to a neuron expressing TrkA, an NGF receptor. | 06-06-2013 |
| 20130216560 | Lipidomic Biomarkers for Identification of High-Risk Coronary Artery Disease Patients - The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications. | 08-22-2013 |
| 20130224225 | ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME USEFUL FOR INHIBITING ACTIVITY OF METALLOPROTEINS - An antibody comprising an antigen recognition region which comprises CDR amino acid sequences set forth in SEQ ID NO: 7, 8, 9, 10, 11 and 12. | 08-29-2013 |
| 20130236478 | PROCESS FOR THE PREPARATION AND USE OF A BIVALENT VACCINE AGAINST MORPHINE-HEROINE ADDICTION - Provided are bivalent immunogenic composition against morphine-heroin addiction comprising a carrier protein (“CP”) and a morphinic product, wherein the CP and the morphinic product are connected by a spacer-linker arm having a total molecular size of 16-21 Å, and methods of using the same. | 09-12-2013 |
| 20130280279 | PHARMACEUTICAL COMPOSITION OF A COMPLEX OF AN ANTI-DIG ANTIBODY AND DIGOXIGENIN THAT IS CONJUGATED TO A PEPTIDE - The present invention relates to a pharmaceutical composition of complex of a monospecific antibody that binds to digoxigenin, and a digoxigenin-conjugated peptide, to the isolated or recovered complex as well as to a method of producing such complex or composition. Furthermore the use of such a pharmaceutical composition as a medicament is described. | 10-24-2013 |
| 20130287799 | ABETA CONFORMER SELECTIVE ANTI-ABETA GLOBULOMER MONOCLONAL ANTIBODIES - The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto. | 10-31-2013 |
| 20140050743 | BINDING PROTEINS TO INHIBITORS OF COAGULATION FACTORS - The present invention relates to the identification and use of antigen-binding regions, antibodies, antigen-binding antibody fragments and antibody mimetics, neutralizing the anti-coagulant effect of an anticoagulant in vitro and/or in vivo. Antibodies and functional fragments of the invention and antibody mimetics can be used to specifically reverse the pharmacological effect of an anticoagulant e.g. a FXa inhibitor for therapeutic (antidote) and/or diagnostic purposes. The invention also provides nucleic acid sequences encoding foregoing molecules, vectors containing the same, pharmaceutical compositions and kits with instructions for use. | 02-20-2014 |
| 20140056923 | METHOD OF TREATING HYPERTENSION DISORDER AND A PHARMACEUTICAL AGENT - A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. | 02-27-2014 |
| 20140112942 | AGONISTIC ANTIBODY TO CD27 - The invention relates to a binding compound, which binds the same epitope of human CD27 as monoclonal antibody hCD27.15, produced by hybridoma hCD27.15 which was deposited with the ATCC in on Jun. 2, 2010 under number PTA-11008. In particular the invention relates to such a binding compound of claim | 04-24-2014 |
| 20140170170 | ANTI-CYANOBACTERIA RECOMBINANT ANTIBODY POLYPEPTIDE, GENE THEREOF, AND PREPARATION METHOD THEREOF - Provided are a hybridoma cell CGMCC No. 4783 that secretes a monoclonal antibody of an anti-cyanobacteria cell surface antigen, and the secreted monoclonal antibody thereof. Also provided are an anti-cyanobacteria recombinant antibody poly-peptide, encoding gene, preparation method and use thereof. The anti-cyanobacteria recombinant antibody polypeptide is composed of an anti-cyanobacteria antibody mimetic polypeptide operably linearly connecting to the carboxyl terminal of an Escherichia coli polypeptide. The anti-cyanobacteria antibody mimetic polypeptide is a polypeptide with cyanobacteria identifying and binding cap-ability designed based on an antigen binding fragment of the monoclonal antibody secreted by the CGMCC No.4783 hybridoma cell. The anti-cyanobacteria recombinant antibody polypeptide directly form an ion channel on the cell membrane of a cyanobacteria to kill the cyanobacteria, targeted killing the cyanobacteria (prokaryote) without killing other beneficial eukaryotic cell algae. | 06-19-2014 |
| 20140178410 | ANTIBODIES AGAINST PHOSPHORYLCHOLINE - The present invention relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein—(a) the VH domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence comprising an amino acid sequence having at least 25%, 50%, 75% or 100% sequence identity to the sequence of SEQ ID NO: 17; a CDR2 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 18; and a CDR3 sequence comprising an amino acid sequence having at least 4%, 9%, 13%, 18%, 22%, 27%, 31%, 36%, 40%, 45%, 50%, 54%, 59%, 63%, 68%, 72%, 77%, 81%, 86%, 90%, 95% or 100% sequence identity to the sequence of SEQ ID NO: 19, 20, 21 or 22; and/or (b) the VL domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR4 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 23 or 24; a CDR5 sequence comprising an amino acid sequence having at least 14%, 28%, 42%, 57%, 71%, 85% or 100% sequence identity to the sequence of SEQ ID NO: 25; a CDR6 sequence comprising an amino acid sequence having at least 11%, 22%, 33%, 44%, 55%, 66%, 77%, 88% or 100% sequence identity to the sequence of SEQ ID NO: 26. | 06-26-2014 |
| 20140186377 | PROSTAGLANDIN E2 BINDING PROTEINS AND USES THEREOF - The present invention encompasses prostaglandin E | 07-03-2014 |
| 20140363450 | Oxidized Cardiolipin as a Novel Pro-Inflammatory Factor - Low levels of antibodies reactive with oxidised Cardiolipin (oxCL) in mammals are related to an increased risk of developing cardiovascular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxCL. Thus, based on their relations methods of monitoring, determining and diagnosing as well as methods of immunisation and therapy of these diseases and conditions are provided. | 12-11-2014 |
| 20150044235 | CARRIER IMMUNOGLOBULINS - Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide. | 02-12-2015 |
| 20150044236 | CARRIER IMMUNOGLOBULINS - Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide. | 02-12-2015 |
| 20160018423 | NON-HIGH DENSITY LIPOPROTEIN DERIVED CVD MARKERS - The present invention inter alia relates to methods and uses involving the determination of lipid/lipid concentration ratios in order to diagnose, predict, prevent and/or treat atherosclerosis or cardiovascular disease (CVD) and its complications including, e.g., acute myocardial infarction. The methods include analyzing lipid concentrations and resulting lipid/lipid concentration ratios of a non-high density lipoprotein samples from patients and comparing them to a control. | 01-21-2016 |
| 20160130366 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE - The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies. | 05-12-2016 |
| 20160154928 | SYSTEMS, METHODS, AND ENVIRONMENT FOR AUTOMATED REVIEW OF GENOMIC DATA TO IDENTIFY DOWNREGULATED AND/OR UPREGULATED GENE EXPRESSION INDICATIVE OF A DISEASE OR CONDITION | 06-02-2016 |
